Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors

Despite having acute and preventive migraine medications available for some time, the adherence rates to these treatments can be essentially abysmal for a number of reasons, from adverse effects to poor response. However, with the recent introduction the calcitonin gene-related peptide (CGRP) inhibitors into the market, there’s a bright light on the horizon.
Even more exciting is that one of the upcoming members of the class, eptinezumab, has shown success in a quarterly infusion dose, as opposed to the other members of the class, which are available in monthly doses. And while eptinezumab still needs regulatory approval, its unique dosing regimen presents a positive for patients in addition to its long-term and sustained efficacy in clinical trials, which has been particularly promising. At the 2019 American Headache Society (AHS) Annual Meeting, July 11-14, 2019, in Philadelphia, Pennsylvania, a number of poster presentations highlighted that data.
While at the meeting, NeurologyLive sat down with Christopher Gottschalk, MD, director, headache medicine, and chief, general neurology, Yale Medicine, to talk about the eptinezumab and the CGRP class, as well as the potential for these therapies to improve the lives of patients with migraine who struggle to remain adherent.

[@harrisoncanning]

Love it

[@phoenixtears25]

Literally THE WORST doctor I’ve ever had!!!! Terrible terrible terrible

[@Notecrusher]

What are this doctor's conflict's of interest? Is he being paid by any of the pharmaceutical companies that stand to profit from CGRP drugs? He paints an overly rosy picture of CGRP antibody drugs. They have performed better than placebo in clinical trials, (with most of the benefit coming from placebo effect), but only marginally better. These drugs are far from "better than anything we've had before", simply because they were developed for the migraine market.
As far as Eptinezumab goes, he may like the idea that he gets to administer the drug to his "patients", but how do migraineurs feel about injecting a chemical with a half-life of 3 months? That's not a risk I would subject my body and my health to, ESPECIALLY with a new drug!

[@phoenixtears25]

Notecrusher yes, he is being paid by companies, he was my ex neurologist. You can even look up how much he gets a year from his sponsoring. I promise he is here for money, and I’ve had many neurologists that were nothing like him

[@phoenixtears25]

Look up Christopher gottschalk in openpaymentsdata.cms.gov